Key Drivers
- Strong margins
- Robust liquidity
- Low leverage
AIAI Summary
GMED is now a hybrid growth-and-transformation story where sustained U.S. spine revenue and an early positive EBITDA contribution from Nevro create meaningful upside, but the investment hinges on management delivering swift margin convergence at Nevro, cutting its SG&A intensity, and preserving free‑cash‑flow via disciplined buybacks and integration execution. Investors should track quarter‑over‑quarter Nevro gross‑margin and SG&A trends, FCF conversion versus capital returns/M&A, and any signs of inventory or intangible impairment as near‑term triggers that will flip the thesis.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Robust liquidity
- •Low leverage
GMED is profitable and cash‑generative with strong liquidity and low leverage, but materially dependent on intangibles and inventory and subject to financing‑flow timing risk.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Nearby floor
- •Resistance capped
GMED is in a short-term downtrend—price fell from $90.59 to $86.26 (~4.8%) over the last month, trading below the last-month 21-day SMA (~$89.6) with resistance near $89.5–$90 and $95–$97 and support around $84.5–$86.0.
~11% drop from late-Feb highs to current level signaling a material retracement
Sentiment & News
Key News Insights:
- •Earnings beat
- •Analyst upgrades
- •Institutional buying
Globus Medical beat Q4/2025 estimates, drew analyst upgrades and growing institutional buys, and shows momentum despite macro/cost risks.
Strengthening fundamentals and rising investor confidence should support near-term upside in GMED, though macro and cost pressures could limit sustained outperformance
Similar Companies in Healthcare
Other companies in the same sector with AI ratings